CN1917902A - 白细胞介素－33（il－33）和il－33受体复合物的用途 - Google Patents

白细胞介素－33（il－33）和il－33受体复合物的用途 Download PDF

Info

Publication number
CN1917902A
CN1917902A CNA2005800050705A CN200580005070A CN1917902A CN 1917902 A CN1917902 A CN 1917902A CN A2005800050705 A CNA2005800050705 A CN A2005800050705A CN 200580005070 A CN200580005070 A CN 200580005070A CN 1917902 A CN1917902 A CN 1917902A
Authority
CN
China
Prior art keywords
leu
ser
val
arg
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800050705A
Other languages
English (en)
Chinese (zh)
Inventor
J·施米茨
M·奥夫特
R·A·卡斯特莱因
J·F·巴赞
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34886190&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1917902(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of CN1917902A publication Critical patent/CN1917902A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
CNA2005800050705A 2004-02-17 2005-02-15 白细胞介素－33（il－33）和il－33受体复合物的用途 Pending CN1917902A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54573004P 2004-02-17 2004-02-17
US60/545,730 2004-02-17

Publications (1)

Publication Number Publication Date
CN1917902A true CN1917902A (zh) 2007-02-21

Family

ID=34886190

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800050705A Pending CN1917902A (zh) 2004-02-17 2005-02-15 白细胞介素－33（il－33）和il－33受体复合物的用途

Country Status (14)

Country Link
US (5) US20050203046A1 (https=)
EP (2) EP2283860A3 (https=)
JP (4) JP4949859B2 (https=)
CN (1) CN1917902A (https=)
AT (1) ATE496636T1 (https=)
AU (1) AU2005215528B2 (https=)
BR (1) BRPI0507808A (https=)
CA (1) CA2555236C (https=)
DE (1) DE602005026105D1 (https=)
NO (1) NO20064193L (https=)
NZ (1) NZ549040A (https=)
TW (2) TW201304802A (https=)
WO (1) WO2005079844A2 (https=)
ZA (1) ZA200606844B (https=)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105007929A (zh) * 2013-03-15 2015-10-28 瑞泽恩制药公司 Il-33拮抗剂和其用途
CN105051063A (zh) * 2013-03-13 2015-11-11 瑞泽恩制药公司 抗-il-33抗体及其用途
CN105980556A (zh) * 2013-12-26 2016-09-28 田边三菱制药株式会社 人抗il－33中和单克隆抗体
CN107109494A (zh) * 2014-11-10 2017-08-29 豪夫迈·罗氏有限公司 Il‑33介导型疾病的治疗方法和诊断方法
CN108064236A (zh) * 2015-03-31 2018-05-22 免疫医疗有限公司 新颖的il33形式、il33的突变形式、抗体、测定及其使用方法
CN108137682A (zh) * 2015-10-06 2018-06-08 瑞泽恩制药公司 与白介素-33(il-33)介导的疾病有关的生物标志物及其用途
CN109863173A (zh) * 2016-10-28 2019-06-07 伊莱利利公司 抗-il-33抗体及其用途
CN111012905A (zh) * 2013-10-07 2020-04-17 宾夕法尼亚大学理事会 具有作为佐剂的白介素-33的疫苗
CN111979198A (zh) * 2013-03-15 2020-11-24 伊利克斯根治疗公司 使用zscan4复壮人细胞的方法
CN112210556A (zh) * 2020-10-15 2021-01-12 扬州大学 一组靶向干扰IL-33表达的shRNA、重组腺病毒载体及其构建方法和应用
CN116396974A (zh) * 2022-02-21 2023-07-07 吉林农业大学 非洲猪瘟病毒抗原蛋白重组表达载体、重组植物乳酸菌及其制备方法和应用
US11725050B2 (en) 2014-11-10 2023-08-15 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
US11834505B2 (en) 2016-06-29 2023-12-05 Checkpoint Therapeutics, Inc. PD-L1-specific antibodies and methods of using the same
WO2025082552A3 (zh) * 2023-10-16 2025-05-30 王琪 负载il33的溶瘤痘苗病毒及其与免疫检查点抑制剂的联合疗法

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002038794A2 (en) 2000-11-09 2002-05-16 The Brigham And Women's Hospital, Inc. Cardiovascular disease diagnostic and therapeutic targets
DK3072978T3 (en) 2002-05-09 2018-09-17 Brigham & Womens Hospital Inc : 1L1RL-1 AS A CARDIOVASCULAR DISEASE MARKER
NZ549040A (en) * 2004-02-17 2009-07-31 Schering Corp Use for interleukin-33 (IL33) and the IL-33 receptor complex
US20120144504A1 (en) * 2005-10-16 2012-06-07 Yeda Research And Development Co. Ltd. Caspase-8 and skin disease
AU2007244927B2 (en) * 2006-04-24 2012-01-12 Critical Care Diagnostics, Inc. Predicting mortality and detecting severe disease
ATE517341T1 (de) * 2006-04-27 2011-08-15 Critical Care Diagnostics Inc Interleukin-33 (il-33) zur diagnose und vorhersage von herz-gefäss-erkrankungen
EP2021796B1 (en) * 2006-05-01 2012-02-08 Critical Care Diagnostics, Inc. Diagnosis of cardiovascular disease
PL2019965T3 (pl) * 2006-05-02 2015-10-30 Critical Care Diagnostics Inc Rozpoznawanie różnicowe chorób układu oddechowego i sercowo-naczyniowego
US8147817B2 (en) * 2006-05-04 2012-04-03 The Brigham And Women's Hospital, Inc. IL-33 in the treatment and diagnosis of diseases and disorders
US7560530B1 (en) 2006-07-20 2009-07-14 Schering Corporation IL-33 receptor
SE532250C2 (sv) * 2006-11-28 2009-11-24 Theravac Pharmaceuticals Ab Nya formuleringar av IL-33 för behandling av inflammatoriska tillstånd med en stark TH2 komponent genom vaccinering
IE20080331A1 (en) * 2007-04-26 2009-07-08 Trinity College Dublin Products for altering cytokine activity and methods therefor
AU2008254704A1 (en) * 2007-05-18 2008-11-27 Medimmune, Llc IL-33 in inflammatory disease
PL2269063T3 (pl) 2008-04-18 2014-04-30 Critical Care Diagnostics Inc Rokowanie ryzyka głównych niekorzystnych zdarzeń sercowych
JP5539660B2 (ja) * 2009-03-10 2014-07-02 公益財団法人ヒューマンサイエンス振興財団 粘膜ワクチン用アジュバント
WO2011031600A1 (en) * 2009-09-10 2011-03-17 Schering Corporation Use of il-33 antagonists to treat fibrotic disease
WO2012113813A1 (en) * 2011-02-23 2012-08-30 F. Hoffmann-La Roche Ag Antibodies against human il33r and uses thereof
FR2972006B1 (fr) 2011-02-24 2016-03-25 Centre Nat Rech Scient Nouveaux fragments d'il-33 superactifs et leurs utilisations
ES2750126T3 (es) 2011-03-17 2020-03-25 Critical Care Diagnostics Inc Procedimientos de predicción del riesgo de un resultado clínico adverso
US9090694B2 (en) 2012-04-30 2015-07-28 Janssen Biotech, Inc. ST2L antibody antagonists
AR091069A1 (es) 2012-05-18 2014-12-30 Amgen Inc Proteinas de union a antigeno dirigidas contra el receptor st2
CN104737170A (zh) 2012-08-21 2015-06-24 重症监护诊断股份有限公司 多标记风险分层
AU2013357427B2 (en) * 2012-12-10 2017-08-31 Universiteit Gent Novel Interleukin-33 inhibitors
WO2014126277A1 (ko) * 2013-02-14 2014-08-21 건국대학교 산학협력단 신규한 인터루킨-33 수용체와 결합 단백질 조성물 및 그 용도
EP2958583B1 (en) 2013-02-22 2018-04-11 Magic Epoch Holdings Limited Il-33 and treatment of neurodegenerative diseases
EP3047024B1 (en) * 2013-09-20 2019-04-24 University Of Virginia Patent Foundation Compositions and methods for treatment of autoimmune and inflammatory diseases and disorders
SG11201605580RA (en) * 2014-01-10 2016-10-28 Anaptysbio Inc Antibodies directed against interleukin-33 (il-33)
WO2015143343A2 (en) 2014-03-21 2015-09-24 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring
EP3134120B1 (en) 2014-04-21 2024-01-24 The Children's Hospital of Philadelphia Compositions and methods for treating cytokine-related disorders
EP3265107B1 (en) 2015-03-02 2024-10-02 180 Therapeutics LP Method of treating a localized fibrotic disorder using a tnf receptor 2 antagonist
JP6991863B2 (ja) * 2015-03-03 2022-02-03 カヴァ ヘルスケア インコーポレイテッド ２型自然リンパ球細胞、インターロイキン３３、及び／またはインターフェロン誘導性タンパク質４４による癌免疫の調節
JP6501650B2 (ja) * 2015-06-25 2019-04-17 田辺三菱製薬株式会社 ヒト抗ｉｌ−３３中和モノクローナル抗体
WO2017009750A1 (en) * 2015-07-10 2017-01-19 The Hong Kong University Of Science And Technology Methods and compositions for treating neurodegenerative and neuroinflammatory conditions
KR101765397B1 (ko) 2015-12-02 2017-08-07 한국과학기술원 질점막을 통한 바이러스 감염 취약 진단 마커로서의 il-33의 용도
JP2019516362A (ja) 2016-04-27 2019-06-20 ファイザー・インク 抗ｉｌ−３３抗体、その組成物、方法および使用
TWI857389B (zh) 2016-12-01 2024-10-01 美商再生元醫藥公司 治療發炎症狀的方法
PE20191548A1 (es) 2017-02-10 2019-10-24 Genentech Inc Anticuerpos contra triptasa, composiciones de estos y usos de estos
US20200339674A1 (en) * 2017-02-17 2020-10-29 The General Hospital Corporation Methods and compositions for treating a brain injury
ES3052989T3 (en) 2017-04-13 2026-01-16 Regeneron Pharma Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding il33 and il1rl1
ES2945740T3 (es) 2017-05-05 2023-07-06 Univ Pittsburgh Commonwealth Sys Higher Education Aplicaciones oculares de vesículas unidas a matriz (MBV)
MY199245A (en) 2017-08-31 2023-10-23 Hyogo College Medicine Il-33 antagonist-containing therapeutic agent for endometriosis
AU2019218128A1 (en) 2018-02-09 2020-09-17 Genentech, Inc. Therapeutic and diagnostic methods for mast cell-mediated inflammatory diseases
IL307286B2 (en) 2018-04-11 2026-03-01 Regeneron Pharma Methods and reagents for IL-33 quantification
CN112805016A (zh) * 2018-05-03 2021-05-14 联邦高等教育系统匹兹堡大学 包含il-33的基质结合囊泡(mbv)及其用途
US11401324B2 (en) 2018-08-30 2022-08-02 HCW Biologics, Inc. Single-chain chimeric polypeptides and uses thereof
US11518792B2 (en) 2018-08-30 2022-12-06 HCW Biologics, Inc. Multi-chain chimeric polypeptides and uses thereof
CA3109361A1 (en) 2018-08-30 2020-03-05 HCW Biologics, Inc. Single-chain and multi-chain chimeric polypeptides and uses thereof
TW202519263A (zh) 2019-03-21 2025-05-16 美商再生元醫藥公司 含有抗il-33抗體之穩定調配物
CN120924491A (zh) 2019-06-21 2025-11-11 免疫生物公司 多链嵌合多肽和其用途
EP3989985A4 (en) * 2019-06-30 2023-09-13 Memorial Sloan Kettering Cancer Center METHODS AND COMPOSITIONS FOR TREATING PANCREATIC CANCER
US20230101029A1 (en) * 2019-10-11 2023-03-30 General Regeneratives (Shanghai) Limited Methods of using il-33 protein in treating cancers
IL292443A (en) * 2019-11-04 2022-06-01 Medimmune Ltd Methods for using IL-33 antagonists
WO2021163299A1 (en) 2020-02-11 2021-08-19 HCW Biologics, Inc. Chromatography resin and uses thereof
AU2021220870A1 (en) 2020-02-11 2022-08-04 Immunitybio, Inc. Methods of treating age-related and inflammatory diseases
CA3169243A1 (en) 2020-02-11 2021-08-19 HCW Biologics, Inc. Methods of activating regulatory t cells
AU2021236306A1 (en) 2020-03-13 2022-09-15 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
CN115836087A (zh) 2020-04-29 2023-03-21 Hcw生物科技公司 抗cd26蛋白及其用途
WO2021247003A1 (en) 2020-06-01 2021-12-09 HCW Biologics, Inc. Methods of treating aging-related disorders
US12024545B2 (en) 2020-06-01 2024-07-02 HCW Biologics, Inc. Methods of treating aging-related disorders
JP2023527869A (ja) 2020-06-01 2023-06-30 エイチシーダブリュー バイオロジックス インコーポレイテッド 加齢関連障害の治療法
EP4430072A1 (en) 2021-11-10 2024-09-18 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
WO2023201311A1 (en) 2022-04-13 2023-10-19 HCW Biologics, Inc. Multi-chain chimeric polypeptide for use in the treatment of treating neuroinflammatory disorder

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US6176962B1 (en) 1990-02-28 2001-01-23 Aclara Biosciences, Inc. Methods for fabricating enclosed microchannel structures
WO1992010210A1 (en) * 1990-12-14 1992-06-25 E.I. Du Pont De Nemours And Company Inhibition of angiogenesis by il-1
US5571702A (en) 1991-03-29 1996-11-05 Genentech, Inc. Amplification method for detection of human PF4A receptors
WO1995001997A1 (en) 1993-07-09 1995-01-19 Smithkline Beecham Corporation RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
US5576191A (en) * 1994-06-17 1996-11-19 Immunex Corporation Cytokine that binds ST2
US6132764A (en) 1994-08-05 2000-10-17 Targesome, Inc. Targeted polymerized liposome diagnostic and treatment agents
US5888530A (en) 1995-07-21 1999-03-30 The General Hospital Corporation Method of enhancing delivery of a pharmaceutical formulation
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US5842787A (en) 1997-10-09 1998-12-01 Caliper Technologies Corporation Microfluidic systems incorporating varied channel dimensions
EP2014770A3 (en) 1997-10-29 2009-02-18 Genentech, Inc. WNT-1 Iinduced secreted polypeptide WISP-2
WO1999032626A1 (en) * 1997-12-23 1999-07-01 Immunex Corporation Sigirr dna and polypeptides
GB9727172D0 (en) * 1997-12-24 1998-02-25 Univ Glasgow Reagents specific for st2l and uses therefor
US6326482B1 (en) 1999-04-23 2001-12-04 Genentech, Inc. SH2 domain-containing peptides
CA2340579A1 (en) 1998-09-01 2000-03-09 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin 18-binding protein
JP2002531466A (ja) 1998-12-01 2002-09-24 プロテイン デザイン ラブス， インコーポレイテッド γ−インターフェロンに対するヒト化抗体
US6323334B1 (en) * 1999-09-24 2001-11-27 Millennium Pharmaceuticals, Inc. Nucleic acid molecules encoding a 103 gene product and uses therefor
WO2001046697A2 (en) 1999-12-21 2001-06-28 Millennium Predictive Medicine Identification, assessment, prevention, and therapy of breast cancer
GB0020685D0 (en) * 2000-08-22 2000-10-11 Novartis Ag Organic compounds
DE60144493D1 (de) 2000-12-08 2011-06-01 Curagen Corp Verfahren zur bestimmung und behandlung von tuberöse-sklerose komplex assoziierten erkrankungen
US20040009481A1 (en) * 2001-06-11 2004-01-15 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer
WO2003016475A2 (en) 2001-08-14 2003-02-27 The General Hospital Corporation Nucleic acid and amino acid sequences involved in pain
WO2002010210A2 (en) 2001-08-28 2002-02-07 Bayer Cropscience Ag Polypeptides for identifying herbicidally active compounds
WO2004056868A2 (en) * 2002-12-19 2004-07-08 Endocube Sas Nf-hev compositions and methods of use
JP2007537717A (ja) 2004-01-07 2007-12-27 ブリストル−マイヤーズ　スクイブ　カンパニー 上皮増殖因子受容体モデュレーターに対する感受性を決定するためのバイオマーカーおよび方法
NZ549040A (en) 2004-02-17 2009-07-31 Schering Corp Use for interleukin-33 (IL33) and the IL-33 receptor complex
US7560530B1 (en) 2006-07-20 2009-07-14 Schering Corporation IL-33 receptor
AU2008254704A1 (en) 2007-05-18 2008-11-27 Medimmune, Llc IL-33 in inflammatory disease

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105051063A (zh) * 2013-03-13 2015-11-11 瑞泽恩制药公司 抗-il-33抗体及其用途
CN105051063B (zh) * 2013-03-13 2019-08-16 瑞泽恩制药公司 抗-il-33抗体及其用途
CN111979198A (zh) * 2013-03-15 2020-11-24 伊利克斯根治疗公司 使用zscan4复壮人细胞的方法
US12478657B2 (en) 2013-03-15 2025-11-25 Elixirgen Therapeutics, Inc. Methods of using Zscan4 for rejuvenating human cells
US12478659B2 (en) 2013-03-15 2025-11-25 Elixirgen Therapeutics, Inc. Methods of using ZSCAN4 for rejuvenating human cells
CN105007929B (zh) * 2013-03-15 2019-05-10 瑞泽恩制药公司 Il-33拮抗剂和其用途
CN105007929A (zh) * 2013-03-15 2015-10-28 瑞泽恩制药公司 Il-33拮抗剂和其用途
CN111012905B (zh) * 2013-10-07 2023-12-22 宾夕法尼亚大学理事会 具有作为佐剂的白介素-33的疫苗
CN111012905A (zh) * 2013-10-07 2020-04-17 宾夕法尼亚大学理事会 具有作为佐剂的白介素-33的疫苗
CN105980556A (zh) * 2013-12-26 2016-09-28 田边三菱制药株式会社 人抗il－33中和单克隆抗体
TWI563003B (en) * 2013-12-26 2016-12-21 Mitsubishi Tanabe Pharma Corp Human anti-il-33 neutralization monoclonal antibody
CN105980556B (zh) * 2013-12-26 2020-10-09 田边三菱制药株式会社 人抗il－33中和单克隆抗体
US11725050B2 (en) 2014-11-10 2023-08-15 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
CN107109494A (zh) * 2014-11-10 2017-08-29 豪夫迈·罗氏有限公司 Il‑33介导型疾病的治疗方法和诊断方法
US11708608B2 (en) 2014-11-10 2023-07-25 Genentech, Inc. Therapeutic and diagnostic methods for IL-33-mediated disorders
CN107109494B (zh) * 2014-11-10 2023-10-27 豪夫迈·罗氏有限公司 Il-33介导型疾病的治疗方法和诊断方法
US11738081B2 (en) 2015-03-31 2023-08-29 Medimmune Limited Polynucleotides encoding IL33 antibodies and methods of using the same
CN108064236B (zh) * 2015-03-31 2021-12-10 免疫医疗有限公司 新颖的il33形式、il33的突变形式、抗体、测定及其使用方法
CN108064236A (zh) * 2015-03-31 2018-05-22 免疫医疗有限公司 新颖的il33形式、il33的突变形式、抗体、测定及其使用方法
CN108137682A (zh) * 2015-10-06 2018-06-08 瑞泽恩制药公司 与白介素-33(il-33)介导的疾病有关的生物标志物及其用途
US11834505B2 (en) 2016-06-29 2023-12-05 Checkpoint Therapeutics, Inc. PD-L1-specific antibodies and methods of using the same
CN109863173A (zh) * 2016-10-28 2019-06-07 伊莱利利公司 抗-il-33抗体及其用途
CN109863173B (zh) * 2016-10-28 2022-06-03 伊莱利利公司 抗-il-33抗体及其用途
CN112210556A (zh) * 2020-10-15 2021-01-12 扬州大学 一组靶向干扰IL-33表达的shRNA、重组腺病毒载体及其构建方法和应用
CN116396974B (zh) * 2022-02-21 2024-02-13 吉林农业大学 非洲猪瘟病毒抗原蛋白重组表达载体、重组植物乳酸菌及其制备方法和应用
CN116396974A (zh) * 2022-02-21 2023-07-07 吉林农业大学 非洲猪瘟病毒抗原蛋白重组表达载体、重组植物乳酸菌及其制备方法和应用
WO2025082552A3 (zh) * 2023-10-16 2025-05-30 王琪 负载il33的溶瘤痘苗病毒及其与免疫检查点抑制剂的联合疗法

Also Published As

Publication number Publication date
CA2555236C (en) 2015-05-05
JP2016034948A (ja) 2016-03-17
ZA200606844B (en) 2008-05-28
JP4949859B2 (ja) 2012-06-13
EP2283860A2 (en) 2011-02-16
AU2005215528B2 (en) 2009-04-30
CA2555236A1 (en) 2005-09-01
EP1725261B1 (en) 2011-01-26
BRPI0507808A (pt) 2007-07-10
JP2007523089A (ja) 2007-08-16
TWI372628B (en) 2012-09-21
JP2011178810A (ja) 2011-09-15
US20050203046A1 (en) 2005-09-15
NZ549040A (en) 2009-07-31
NO20064193L (no) 2006-11-16
AU2005215528A1 (en) 2005-09-01
US20070160579A1 (en) 2007-07-12
ATE496636T1 (de) 2011-02-15
WO2005079844A2 (en) 2005-09-01
EP2283860A3 (en) 2013-06-05
TW200539891A (en) 2005-12-16
US9970944B2 (en) 2018-05-15
DE602005026105D1 (de) 2011-03-10
EP1725261A2 (en) 2006-11-29
TW201304802A (zh) 2013-02-01
US20140140954A1 (en) 2014-05-22
JP2014098026A (ja) 2014-05-29
US20180128837A1 (en) 2018-05-10
WO2005079844A3 (en) 2005-11-24
US20090041718A1 (en) 2009-02-12

Similar Documents

Publication Publication Date Title
CN1917902A (zh) 白细胞介素－33（il－33）和il－33受体复合物的用途
CN1759123A (zh) Il－23激动剂及拮抗剂的用途；相关试剂
CN1247780C (zh) 哺乳动物细胞因子样多肽－10
CN1125082C (zh) 人类趋化因子β－8,趋化因子β－1和巨噬细胞炎性蛋白－4
CN1906297A (zh) Il－23及其受体、相关试剂和方法
CN1849131A (zh) 用白介素－21/白介素－21受体的激动剂治疗免疫性疾病
CN1575337A (zh) 哺乳动物细胞因子受体亚单位蛋白、相关试剂及方法
KR20150127185A (ko) 비글리코실화 Fc-함유 폴리펩티드
CN1378595A (zh) 作为zalpha受体之配体的人细胞因子及其用途
EP4385573A2 (en) Interleukin-2 muteins for the expansion of t-regulatory cells
CN1665933A (zh) 用于治疗肿瘤的免疫缀合物
CN1589902A (zh) 抗－LT－β－R抗体在制备药用组合物中的应用
CN1891714A (zh) 单纯疱疹病毒进入介体的配体和使用方法
CN1921886A (zh) 调节细胞因子活性的方法；相关药剂
CN1323716C (zh) Sarp－1在治疗和/或预防硬皮病中的应用
CN1305529C (zh) Il－18抑制剂在治疗或预防中枢神经系统损伤中的应用
CN1195853C (zh) 神经营养因子nnt－1
CN1909926A (zh) 能够结合il－18bp和抑制第二细胞因子活性的细胞因子的用途
CN1568193A (zh) Il－18抑制剂在过敏反应疾病中的应用
CN1634991A (zh) 人源抗破伤风毒素单克隆抗体及其制备方法和用途
CN1198842C (zh) 具有细胞趋化作用和造血刺激活性的趋化素样因子
CN1230993A (zh) 制备血小板生成素多肽的表达载体、细胞和方法
CN1638799A (zh) 人类肥大细胞表达的膜蛋白
HK40112585A (en) Interleukin-2 muteins for the expansion of t-regulatory cells
CN1148381C (zh) 新的人趋化因子巨噬细胞炎性蛋白、其编码序列及用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: new jersey

Applicant after: Schering Corporation

Address before: new jersey

Applicant before: SCHERING CORP (US)

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: SCHERING CORP (US) TO: MSD CORP.

AD01 Patent right deemed abandoned
AD01 Patent right deemed abandoned

Effective date of abandoning: 20170524